Last viewed:
ABBV
Prices are updated after-hours
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
(0.0% 1d)
(-7.3% 1m)
(2.1% 1y)
(0.0% 2d)
(0.8% 3d)
(2.2% 7d)
(NaN%
volume)
Earnings Calendar:
Market Cap: $ 294,653,364,441
http://www.abbvie.com
Sec
Filling
|
Patents
| 30000 employees
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
cancer
hiv
autoimmunity
hepatitis
fibrosis
metabolic
parkinson
neurological
Drugs
Alcohol - Hand Sanitizer
(Alcohol )
Androgel
(Testosterone )
Creon
(Pancrelipase )
Depakote
(Divalproex Sodium )
Depakote ER
(Divalproex Sodium )
Depakote Sprinkles
(Divalproex Sodium )
Duopa
(Carbidopa and Levodopa )
Gengraf
(Cyclosporine )
Humira
(Adalimumab )
Kaletra
(Lopinavir and Ritonavir )
K-Tab
(Potassium Chloride )
Lupaneta Pack
(leuprolide acetate and norethindrone acetate )
Lupron Depot
(leuprolide acetate )
Lupron Depot-PED
(leuprolide acetate )
Marinol
(Dronabinol )
Mavyret
(Glecaprevir and Pibrentasvir )
Niaspan
(Niacin )
Nimbex
(Cisatracurium besylate )
Norvir
(Ritonavir )
Oriahnn
(Elagolix and Estradiol and Norethisterone )
Orilissa
(Elagolix )
Rinvoq
(Upadacitinib )
Skyrizi
(Risankizumab-rzaa )
Survanta
(Beractant )
Synthroid
(Levothyroxine Sodium )
Tarka
(Trandolapril and Verapamil Hydrochloride )
Tricor
(Fenofibrate )
Trilipix
(Fenofibric Acid )
Ultane
(Sevoflurane )
Venclexta
(Venetoclax )
Viekira Pak
(Dasabuvir and Ombitasvir and Paritaprevir and Ritonavir )
Zemplar
(Paricalcitol )
add to watch list
Paper trade
email alert is off
Press-releases
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18
(Crawled : 19:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| 0.75%
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq
positive
cell
results
study
Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027, Technavio
Published: 2024-04-17
(Crawled : 00:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| 0.75%
| O: 0.75%
H: 0.0%
C: 0.0%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
| -0.75%
| O: -0.75%
H: 0.0%
C: 0.0%
therapeutics
market
Biologic Therapeutics Market size is set to grow by USD 286.12 billion from 2023-2027, Introduction of biosimilars boost the market, Technavio
Published: 2024-04-15
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -0.29%
| O: -1.75%
H: 0.85%
C: 0.85%
AZNCF
|
News
|
$138.24
-4.19%
800
|
Health Technology
| -0.47%
| O: 2.1%
H: 0.0%
C: -2.52%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
| -1.19%
| O: -1.46%
H: 0.0%
C: 0.0%
GSK
|
News
|
$39.75
1.22%
0.0%
1.6M
|
Health Technology
| -2.22%
| O: -1.19%
H: 0.52%
C: -0.17%
BAX
|
$39.47
-0.45%
0.0%
2.8M
|
Health Technology
| -0.85%
| O: -0.1%
H: 0.13%
C: -1.08%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| 2.16%
| O: 0.32%
H: 0.96%
C: 0.22%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -2.9%
| O: -2.13%
H: 0.0%
C: 0.0%
BMRN
|
$88.68
-1.54%
-1.57%
1.8M
|
Health Technology
| -0.46%
| O: -0.72%
H: 0.0%
C: 0.0%
AZN
|
News
|
$68.56
0.29%
0.29%
4.7M
|
Health Technology
| -0.68%
| O: -0.64%
H: 0.45%
C: -0.04%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
| -0.22%
| O: 0.41%
H: 0.0%
C: 0.0%
set
therapeutics
market
Gastrointestinal Therapeutics and Diagnostics: Propelling Global Markets with Cutting-Edge Technologies by BCC Research LLC
Published: 2024-04-15
(Crawled : 11:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -0.22%
| O: -0.53%
H: 0.61%
C: 0.61%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
| -2.2%
| O: -0.04%
H: 0.0%
C: 0.0%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| 0.52%
| O: 0.13%
H: 0.11%
C: -1.73%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -1.01%
| O: 1.95%
H: 0.0%
C: 0.0%
research
global
gastrointestinal
therapeutics
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Published: 2024-04-12
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| -1.41%
| O: -1.92%
H: 0.0%
C: 0.0%
qulipta
abbvie
treatment
for
migraine
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08
(Crawled : 18:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| 0.01%
| O: 2.24%
H: 0.0%
C: -0.8%
AZNCF
|
News
|
$138.24
-4.19%
800
|
Health Technology
| 1.57%
| O: -3.43%
H: 6.21%
C: 6.21%
VTRS
A
|
$11.25
1.17%
1.16%
4.7M
|
Health Technology
| -5.76%
| O: -0.25%
H: 1.1%
C: -0.17%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
| -2.83%
| O: -0.05%
H: 0.43%
C: -0.27%
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| -5.88%
| O: -0.08%
H: 0.04%
C: -0.35%
BHC
|
$8.69
1.05%
0.0%
2.9M
|
Health Technology
| -16.04%
| O: 0.38%
H: 0.0%
C: -7.27%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| -1.64%
| O: 0.77%
H: 1.63%
C: 0.35%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -3.02%
| O: 0.84%
H: 0.0%
C: 0.0%
AZN
|
News
|
$68.56
0.29%
0.29%
4.7M
|
Health Technology
| 1.21%
| O: 0.18%
H: 0.3%
C: 0.19%
eczema
dermatitis
set
therapeutics
market
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
Published: 2024-04-08
(Crawled : 12:30)
- globenewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| -1.64%
| O: 0.77%
H: 1.63%
C: 0.35%
CHRS
|
$2.06
3.0%
2.91%
2.9M
|
Health Technology
| -11.52%
| O: 0.82%
H: 3.88%
C: 2.45%
chs-1000
preclinical
for
meeting
AbbVie to Host First-Quarter 2024 Earnings Conference Call
Published: 2024-04-04
(Crawled : 12:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| -8.76%
| O: -1.86%
H: 0.03%
C: -5.49%
conference
abbvie
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
Published: 2024-04-01
(Crawled : 12:00)
- globenewswire.com
NXGL
|
$2.21
-1.4%
1.2K
|
Manufacturing
| -17.58%
| O: 1.83%
H: 0.0%
C: -19.42%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| -9.3%
| O: -0.12%
H: 0.01%
C: -0.62%
year
revenue
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
Published: 2024-03-29
(Crawled : 18:00)
- prnewswire.com
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
| Email alert
Add to watchlist
GMAB
|
$28.72
1.38%
1.36%
360K
|
Health Technology
| Email alert
Add to watchlist
GILD
|
$66.77
0.92%
0.91%
11M
|
Health Technology
| Email alert
Add to watchlist
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| Email alert
Add to watchlist
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
| Email alert
Add to watchlist
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| Email alert
Add to watchlist
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
| Email alert
Add to watchlist
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
| Email alert
Add to watchlist
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| Email alert
Add to watchlist
GNMSF
|
$290.38
3.83%
220
|
Health Technology
| Email alert
Add to watchlist
research
global
leukemia
therapeutics
market
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001415889-24-006165
4
2024-03-01
2024-02-23
Sell
M
14140
17380
0001415889-24-006165
4
2024-03-01
2024-02-28
Sell
F
11634
15431
0001415889-24-006165
4
2024-03-01
2024-02-23
Sell
S
14140
27065
0001415889-24-006165
4
2024-03-01
2024-02-23
Buy
M
14140
41205